Abstract
To design and evaluate the potential use of thioalkylated mannose-modified dendrimer (generation 3; G3) conjugates with α-cyclodextrin (Man-S-α-CDE (G3)) as novel antigen-presenting cell (APC)-selective siRNA carriers, we investigated the RNAi effects of siRNA complexes with Man-S-α-CDEs (G3). Man-S-α-CDE (G3, average degree of substitution of mannose (DSM) 4)/siRNA complex had the potent RNAi effects in both NR8383 cells, a rat alveolar macrophage cell line, and JAWSII cells, a mouse dendritic cell line, through adequate physicochemical properties, mannose receptor (MR)-mediated cellular uptake, and efficient phagosomal escape of the siRNA complex. In addition, cytotoxic activities of the siRNA complexes with α-CDE (G3, DS2) and Man-S-α-CDE (G3, DSM4) were almost negligible up to a charge ratio of 100 (carrier/siRNA). Taken together, these results suggest that Man-S-α-CDE (G3, DSM4) has the potential for a novel APC-selective siRNA carrier.
Similar content being viewed by others
References
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806–11.
Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev. 2009;61:850–62.
Watts JK, Corey DR. Clinical status of duplex RNA. Bioorg Med Chem Lett. 2010;20:3203–7.
Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med. 2003;9:347–51.
Zhou J, Rossi JJ. Aptamer-targeted cell-specific RNA interference. Silence. 2010;1:4.
Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discov. 2005;4:581–93.
Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8:129–38.
Xiao B, Wang X, Qiu Z, Ma J, Zhou L, Wan Y, et al. A dual-functionally modified chitosan derivative for efficient liver-targeted gene delivery. J Biomed Mater Res A. 2013;101:1888–97.
Diebold SS, Plank C, Cotten M, Wagner E, Zenke M. Mannose receptor-mediated gene delivery into antigen presenting dendritic cells. Somat Cell Mol Genet. 2002;27:65–74.
East L, Isacke CM. The mannose receptor family. Biochim Biophys Acta. 2002;1572:364–86.
Sato Y, Beutler E. Binding, internalization, and degradation of mannose-terminated glucocerebrosidase by macrophages. J Clin Invest. 1993;91:1909–17.
Kim N, Jiang D, Jacobi AM, Lennox KA, Rose SD, Behlke MA, et al. Synthesis and characterization of mannosylated pegylated polyethylenimine as a carrier for siRNA. Int J Pharm. 2012;427:123–33.
Jain A, Agarwal A, Majumder S, Lariya N, Khaya A, Agrawal H, et al. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release. 2010;148:359–67.
Jain SK, Gupta Y, Jain A, Saxena AR, Khare P, Jain A. Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomedicine. 2008;4:41–8.
Jiang HL, Kang ML, Quan JS, Kang SG, Akaike T, Yoo HS, et al. The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization. Biomaterials. 2008;29:1931–9.
Abdou S, Collomb J, Sallas F, Marsura A, Finance C. β-Cyclodextrin derivatives as carriers to enhance the antiviral activity of an antisense oligonucleotide directed toward a coronavirus intergenic consensus sequence. Arch Virol. 1997;142:1585–602.
Croyle MA, Roessler BJ, Hsu CP, Sun R, Amidon GL. β Cyclodextrins enhance adenoviral-mediated gene delivery to the intestine. Pharm Res. 1998;15:1348–55.
Freeman DJ, Niven RW. The influence of sodium glycocholate and other additives on the in vivo transfection of plasmid DNA in the lungs. Pharm Res. 1996;13:202–9.
Uekama K, Otagiri M. Cyclodextrins in drug carrier systems. Crit Rev Ther Drug Carrier Syst. 1987;3:1–40.
Kihara F, Arima H, Tsutsumi T, Hirayama F, Uekama K. Effects of structure of polyamidoamine dendrimer on gene transfer efficiency of the dendrimer conjugate with α-cyclodextrin. Bioconjug Chem. 2002;13:1211–9.
Kihara F, Arima H, Tsutsumi T, Hirayama F, Uekama K. In vitro and in vivo gene transfer by an optimized α-cyclodextrin conjugate with polyamidoamine dendrimer. Bioconjug Chem. 2003;14:342–50.
Hayashi Y, Mori Y, Yamashita S, Motoyama K, Higashi T, Jono H, et al. Potential use of lactosylated dendrimer (G3)/α-cyclodextrin conjugates as hepatocyte-specific siRNA carriers for the treatment of familial amyloidotic polyneuropathy. Mol Pharm. 2012;9:1645–53.
Wada K, Arima H, Tsutsumi T, Chihara Y, Hattori K, Hirayama F, et al. Improvement of gene delivery mediated by mannosylated dendrimer/α-cyclodextrin conjugates. J Control Release. 2005;104:397–413.
Tsutsumi T, Hirayama F, Uekama K, Arima H. Evaluation of polyamidoamine dendrimer/α-cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering RNA (siRNA). J Control Release. 2007;119:349–59.
Chiu YL, Ali A, Chu CY, Cao H, Rana TM. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol. 2004;11:1165–75.
Arima H, Tsutsumi T, Yoshimatsu A, Ikeda H, Motoyama K, Higashi T, et al. Inhibitory effect of siRNA complexes with polyamidoamine dendrimer/α-cyclodextrin conjugate (generation 3, G3) on endogenous gene expression. Eur J Pharm Sci. 2011;44:375–84.
Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials. 2010;31:6867–75.
Xiao W, Sun YX, Cheng H, Zeng X, Zhang XZ, Zhuo RX. Inhibition of enhanced green fluorescent protein expression by (dextran-hexamethylenediisocyanate)-g-polyethylenimine/siRNA complexes. J Microencapsul. 2010;27:447–52.
Diaz-Moscoso A, Guilloteau N, Bienvenu C, Mendez-Ardoy A, Jimenez Blanco JL, Benito JM, et al. Mannosyl-coated nanocomplexes from amphiphilic cyclodextrins and pDNA for site-specific gene delivery. Biomaterials. 2011;32:7263–73.
Kelly C. Mannosylated liposomes for targeted delivery of siRNA to alveolar macrophages. in Proceedings of the 7th British Society for Gene Therapy Annual Conference. London, UK; 2010.
Bird L. Innate immunity: cargo-driven phagosome fate. Nat Rev Immunol. 2004;4:494.
Arima H, Kihara F, Hirayama F, Uekama K. Enhancement of gene expression by polyamidoamine dendrimer conjugates with α-, β-, and γ-cyclodextrins. Bioconjug Chem. 2001;12:476–84.
Hillaireau H. P. C. Nanocarriers' entry into the cell: relevance to drug delivery. Cel Mol Life Sci. 2009;66:2873–96.
Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release. 2010;145:182–95.
Boskovic J, Arnold JN, Stilion R, Gordon S, Sim RB, Rivera-Calzada A, et al. Structural model for the mannose receptor family uncovered by electron microscopy of Endo180 and the mannose receptor. J Biol Chem. 2006;281:8780–7.
Galustian C, Park CG, Chai W, Kiso M, Bruening SA, Kang YS, et al. High and low affinity carbohydrate ligands revealed for murine SIGN-R1 by carbohydrate array and cell binding approaches, and differing specificities for SIGN-R3 and langerin. Int Immunol. 2004;16:853–66.
Acknowledgments
This work was partially supported by Grant-in-Aid for Scientific Research (C) from Japan Society for the Promotion of Science (23590045).
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplementary Figure 1
FAB-MS (a) and 1H-NMR (b) spectra of 1-α-d-mannosyl-oxypropyl-thio-ethyl-carboxylic acid (PPTX 138 kb)
Supplementary Figure 2
1H-NMR spectra of Man-S-α-CDEs (G3) in D2O (PPTX 73.3 kb)
Supplementary Figure 3
Intracellular distribution of TRITC-Man-S-α-CDE (G3, DSM4) after transfection with siRNA complex in NR8383 cells. TRITC-Man-S-α-CDE (G3, DSM4)/siRNA complex was incubated for 1 h. The amount of siRNA was 10 μg. The charge ratio of carrier/siRNA was 50/1 (PPTX 1.65 MB )
Supplementary Figure 4
Effects of Man-S-α-CDE (G3, DSM4)/siRNA complex on expression of INF-β mRNA in NR8383 cells (PPTX 49.1 kb)
Supplementary Figure 5
Proposed scheme for APC-selective RNAi efficiency of Man-S-α-CDE (G3, DSM4)/siRNA complex (PPTX 107 kb)
Rights and permissions
About this article
Cite this article
Motoyama, K., Mitsuyasu, R., Akao, C. et al. Design and Evaluation of Thioalkylated Mannose-Modified Dendrimer (G3)/α-Cyclodextrin Conjugates as Antigen-Presenting Cell-Selective siRNA Carriers. AAPS J 16, 1298–1308 (2014). https://doi.org/10.1208/s12248-014-9665-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-014-9665-9